…
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. It serves providers, payers, and the government, as well as the higher education sector. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
American Well Corporation operates a telehealth platform that connects patients, healthcare providers and payers to deliver virtual care and digital health services. Long-term growth may be supported by secular adoption of telemedicine, expansion of enterprise contracts with health systems and insurers, and broader integration of digital care tools into care pathways. The company may appeal to investors because it appears positioned with an enterprise-focused, scalable software model and existing client relationships that could support recurring revenue growth.
Principal risks include intense competition from established telehealth and technology companies, dependence on reimbursement and regulatory policy, execution and profitability challenges, and potential customer concentration and data security exposures.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -94.53M | -209.89M | -675.31M | -269.73M | -179.03M |
| Minority interest | -0.73M | 4.50M | 2.98M | 1.64M | 0.45M |
| Net income | -95.70M | -208.14M | -675.16M | -269.79M | -173.65M |
| Selling general administrative | 88.05M | 121.17M | 126.64M | 146.35M | 94.62M |
| Selling and marketing expenses | 43.27M | 76.27M | 86.46M | 81.63M | 66.15M |
| Gross profit | 132.86M | 98.95M | 94.76M | 116.77M | 104.31M |
| Reconciled depreciation | 33.96M | 32.97M | 29.84M | 26.17M | 16.09M |
| Ebit | -105.27M | -217.53M | -255.66M | -275.85M | -179.15M |
| Ebitda | -71.31M | -184.56M | -224.15M | -249.69M | -163.06M |
| Depreciation and amortization | 33.96M | 32.98M | 31.51M | 26.17M | 16.09M |
| Non operating income net other | - | - | - | -2.28M | -3.13M |
| Operating income | -105.27M | -217.53M | -692.14M | -275.85M | -179.15M |
| Other operating expenses | 354.60M | 471.90M | 951.19M | 553.04M | 431.94M |
| Interest expense | 3.80M | - | 19.42M | 6.12M | 0.12M |
| Tax provision | 0.43M | 2.75M | 3.15M | 0.06M | -5.38M |
| Interest income | 3.80M | 10.76M | 15.26M | 6.12M | 0.12M |
| Net interest income | 3.80M | 10.76M | 15.26M | 6.12M | 0.12M |
| Income tax expense | 0.43M | 2.75M | 3.86M | 0.06M | -5.38M |
| Total revenue | 249.32M | 254.36M | 259.05M | 277.19M | 252.79M |
| Total operating expenses | 238.13M | 316.49M | 786.90M | 392.62M | 283.46M |
| Cost of revenue | 116.47M | 155.41M | 164.29M | 160.42M | 148.47M |
| Total other income expense net | 10.74M | 7.65M | 16.83M | 6.12M | 0.12M |
| Net income from continuing ops | -94.97M | -212.64M | -690.72M | -272.07M | -176.78M |
| Net income applicable to common shares | - | - | - | -270.43M | -176.33M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 323.79M | 435.97M | 589.71M | 1217.56M | 1445.84M |
| Intangible assets | 66.07M | 101.54M | 120.25M | 134.98M | 152.41M |
| Other current assets | 13.47M | 13.93M | 16.75M | 19.57M | 21.98M |
| Total liab | 76.00M | 119.72M | 109.52M | 133.71M | 184.96M |
| Total stockholder equity | 235.58M | 304.77M | 464.22M | 1063.88M | 1239.26M |
| Deferred long term liab | - | - | - | 3.39M | 2.03M |
| Other current liab | 45.31M | 49.33M | 35.41M | 54.26M | 58.71M |
| Common stock | 0.17M | 0.16M | 2.88M | 2.77M | 2.62M |
| Capital stock | 0.17M | 0.16M | 2.88M | 2.77M | 2.62M |
| Retained earnings | -2061.63M | -1965.92M | -1757.78M | -1082.03M | -811.28M |
| Other liab | - | - | - | 7.86M | 28.64M |
| Good will | - | - | 0.00M | 435.28M | 442.76M |
| Other assets | - | - | - | 6.16M | 4.54M |
| Cash | 182.33M | 228.32M | 372.04M | 538.55M | 746.42M |
| Total current liabilities | 73.21M | 111.26M | 93.80M | 114.06M | 141.63M |
| Current deferred revenue | 22.62M | 53.23M | 46.37M | 49.51M | 68.84M |
| Net debt | -177.80M | -220.12M | -360.25M | -523.70M | -729.80M |
| Short term debt | 3.63M | 3.69M | 7.16M | 3.06M | 1.92M |
| Short long term debt total | 4.52M | 8.20M | 11.79M | 14.84M | 16.61M |
| Other stockholder equity | 2309.14M | 2286.38M | 2234.77M | 2160.11M | 2054.28M |
| Property plant equipment | - | - | - | 1.01M | 18.66M |
| Total current assets | 246.68M | 316.99M | 449.58M | 626.62M | 827.30M |
| Long term investments | 0.00M | 1.50M | 1.18M | 0.00M | 0.17M |
| Net tangible assets | - | - | - | 493.62M | 644.09M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 49.69M | 71.89M | 54.15M | 58.37M | 51.38M |
| Inventory | 1.19M | 2.86M | 6.65M | 8.74M | 7.53M |
| Accounts payable | 1.65M | 5.01M | 4.86M | 7.24M | 12.16M |
| Noncontrolling interest in consolidated entity | - | - | - | 19.97M | 21.62M |
| Accumulated other comprehensive income | -12.10M | -15.84M | -15.65M | -16.97M | -6.35M |
| Common stock total equity | - | - | - | 2.77M | 2.62M |
| Retained earnings total equity | - | - | - | -1082.03M | -811.28M |
| Non currrent assets other | 6.08M | 8.36M | 7.67M | 6.16M | 2.52M |
| Deferred long term asset charges | - | - | - | 3.39M | 2.03M |
| Non current assets total | 77.11M | 118.97M | 140.12M | 590.94M | 618.54M |
| Capital lease obligations | 4.52M | 8.20M | 11.79M | 14.84M | 16.61M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -1.00M | -18.65M | 126.19M | -11.63M | 97.45M |
| Change to liabilities | - | - | - | 4.16M | -3.82M |
| Total cashflows from investing activities | 17.10M | -18.65M | -19.17M | -11.63M | -59.63M |
| Total cash from financing activities | 0.84M | 1.38M | 2.15M | -3.61M | 5.75M |
| Change to operating activities | - | - | - | 5.77M | -24.98M |
| Net income | -95.70M | -208.14M | -675.16M | -272.07M | -176.78M |
| Change in cash | -45.99M | -143.72M | -166.51M | -207.87M | -195.50M |
| Begin period cash flow | 229.11M | 372.83M | 539.34M | 747.21M | 942.71M |
| End period cash flow | 183.12M | 229.11M | 372.83M | 539.34M | 747.21M |
| Total cash from operating activities | -65.95M | -127.34M | -148.34M | -192.32M | -141.54M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 33.96M | 33.43M | 31.92M | 26.17M | 16.09M |
| Other cashflows from investing activities | -0.20M | -18.65M | -18.88M | -10.15M | -156.53M |
| Change to inventory | 1.17M | 1.90M | 2.08M | -1.21M | 1.60M |
| Change to account receivables | 12.22M | -25.01M | 3.25M | -8.14M | -0.51M |
| Sale purchase of stock | -0.00M | -0.00M | -0.59M | -0.36M | -15.04M |
| Other cashflows from financing activities | 0.84M | 1.38M | 2.73M | -8.99M | -123.31M |
| Change to netincome | - | - | - | 68.23M | 43.72M |
| Capital expenditures | 0.02M | 15.22M | 15.25M | 10.45M | 0.56M |
| Change receivables | - | - | - | -8.14M | -0.51M |
| Cash flows other operating | - | - | - | -9.46M | -11.80M |
| Cash and cash equivalents changes | - | - | - | -207.56M | -195.42M |
| Change in working capital | -26.80M | -9.98M | -15.51M | -28.10M | -27.71M |
| Stock based compensation | 22.01M | 47.54M | 72.25M | 67.67M | 43.81M |
| Other non cash items | 1.68M | 57.59M | 438.40M | 16.53M | 9.31M |
| Free cash flow | -65.97M | -142.56M | -163.59M | -202.77M | -142.10M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AMWL American Well Corp |
- -% |
11.91 | - | - | 0.42 | 0.46 | 0.73 | -0.82 |
| VEEV Veeva Systems Inc Class A |
-1.60 0.53% |
302.12 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
- -% |
144.00 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
6.32 8.31% |
82.37 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.20 3.40% |
5.69 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. It serves providers, payers, and the government, as well as the higher education sector. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ido Schoenberg M.D. | Chairman & Co-CEO | 1965 |
| Dr. Roy Schoenberg M.D., M.P.H., MPH | Pres, Co-CEO & Director | 1969 |
| Mr. Robert Shepardson | CFO & Exec. VP | 1965 |
| Mr. Kurt Knight | Exec. VP & COO | 1979 |
| Ms. Phyllis I. Gotlib | Exec. VP & Pres of International | 1958 |
| Mr. Paul Francis McNeice | VP of Accounting | 1977 |
| Mr. Serkan Kutan | Chief Technology Officer | 1977 |
| Mr. Tim Conway | Chief Information Officer | NA |
| Mr. Bradford F. Gay | Sr. VP & Gen. Counsel | 1977 |
| Ms. Susan Worthy | Chief Marketing Officer | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.